A Single-Site Mutant and Revertants Arising in Vivo Define Early Steps in the Pathogenesis of Venezuelan Equine Encephalitis Virus  by Aronson, Judith F. et al.
MVirology 270, 111–123 (2000)
doi:10.1006/viro.2000.0241, available online at http://www.idealibrary.com onA Single-Site Mutant and Revertants Arising in Vivo Define Early Steps
in the Pathogenesis of Venezuelan Equine Encephalitis Virus
Judith F. Aronson,1 Franziska B. Grieder,2 Nancy L. Davis, Peter C. Charles,
Travis Knott, Kevin Brown, and Robert E. Johnston3
Department of Microbiology and Immunology, University of North Carolina School of Medicine, Chapel Hill, North Carolina 27599-7290
Received October 11, 1999; returned to author for revision December 17, 1999; accepted February 7, 2000
The early stages of Venezuelan equine encephalitis virus (VEE) pathogenesis in the mouse model have been examined
using a genetic approach. Disease progression of a molecularly cloned single-site mutant was compared with that of the
parental virus to determine the step in the VEE pathogenetic sequence at which the mutant was blocked. Assuming that such
a block constitutes a genetic screen, isolates from different tissues thought to be distal to the block in the VEE pathogenetic
sequence were analyzed to determine the pathogenetic step at which revertants of the mutant were selected. Directed
mutation and analysis of reversion in vivo provide two powerful genetic tools for the dissection of the wild-type VEE
pathogenetic sequence. Virus from the parental virulent clone, V3000, first replicated in the draining lymph node after
subcutaneous inoculation in the left rear footpad. Movement of a cloned avirulent mutant, V3010 (E2 76 Glu to Lys), to the
draining lymph node was impaired, replication in the node was delayed, and spread beyond the draining lymph node was
sporadic. Serum, contralateral lymph node, spleen, and brain isolates from V3010 inoculated animals were invariably
revertant with respect to sequence at E2 76 and/or virulence in mice. Revertants isolated from serum and contralateral lymph
node retained the V3010 E2 Lys 76 mutation but also contained a second-site mutation, Glu to Lys at E2 116. Modification
of the V3010 clone by addition of the second-site mutation at E2 116 produced a virus that bypassed the V3010 block at the
draining lymph node but that did not possess full wild-type capacity for replication in the central nervous system or for
induction of mortality. A control construct containing only the E2 116 reverting mutation on the V3000 background was
identical to V3000 in terms of early pathogenetic steps and virulence. Therefore, analysis of mutant replication and reversion
in vivo suggested (1) that the earliest steps in VEE pathogenesis are transit to the draining lymph node and replication at that
site, (2) that the mutation in V3010 impairs transit to the draining lymph node and blocks dissemination to other tissues, and
(3) that reversion can overcome the block without restoring full virulence. © 2000 Academic Press
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iINTRODUCTION
Classical histopathogenesis studies have laid the
groundwork for current understanding of several human
and experimental viral infections, including those caused
by alphaviruses (Fenner, 1949; Nathanson, 1980; Mims et
al., 1995; Roberts, 1962; Johnson, 1965; Jackson et al.,
1991). These descriptive approaches have outlined path-
ways of viral spread in the infected host. However, mo-
lecular methodologies, including reverse genetics, make
it possible to elucidate specific viral genetic features that
are associated with virulence and pathways of dissem-
ination.
Molecular genetic studies of virus pathogenesis have
their antecedents in experiments that examined the ef-
1 Present address: Department of Pathology, The University of Texas
edical Branch, Galveston, TX 77555-0605.
2 Present address: Department of Microbiology, School of Medicine,
Uniformed Services University of the Health Sciences, 4301 Jones
Bridge Road, Bethesda, MD 20914-4799.1
m
3 To whom correspondence and reprint requests should be ad-
dressed. Fax: (919) 962-8103. E-mail: rjohnst@med.unc.edu.
111fects of strain differences and mutation on virus viru-
lence and tissue tropism. Among these are early studies
with reovirus (Spriggs et al., 1983; Tyler et al., 1986),
lymphocytic choriomeningitis virus (Ahmed et al., 1984;
hmed and Oldstone, 1988), bunyaviruses (Endres et al.,
991), and Sindbis virus (Davis et al., 1986). With the
dvent of molecular clones of poliovirus (Racaniello and
altimore, 1981) and alphaviruses (Rice et al., 1987;
avis et al., 1989; Liljestro¨m et al., 1991; Kuhn et al.,
1991), it became possible to unequivocally assign patho-
genesis functions to particular nucleotide substitutions
by comparing otherwise isogenic virus clones (e.g., Polo
et al., 1988; Lustig et al., 1988; Westrop et al., 1989;
ucker and Griffin, 1991; Davis et al., 1991; Atkins et al.,
994). We have continued the evolution of this genetic
pproach in these studies of Venezuelan equine enceph-
litis virus (VEE).
The pathogenesis of VEE in the mouse consists of a
eries of defined steps from infection of the animal until
ts death as a consequence of encephalitis (Davis et al.,
994; Grieder et al., 1995). This pathogenetic sequence
ay be viewed as analogous in concept to a biochemical
0042-6822/00 $35.00
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112 ARONSON ET AL.pathway in which each step consists of a distinct enzy-
matic reaction that converts one intermediate into the
next, culminating in the synthesis of the final product.
Mutants that fail to synthesize the final product are de-
fective in one of the enzymes of the pathway and accu-
mulate the intermediate upon which that enzyme nor-
mally acts. The examination of multiple individual mu-
tants illuminates both the specific enzymes and the
intermediates comprising the pathway. In the context of
viral pathogenesis, each step is a distinct interaction
between the virus and specific cells and/or tissues that
occurs in a milieu dynamically changing during the host
response to infection. Each of these interactions governs
the progression of the infection to its next stage, culmi-
nating in overt disease and/or death. A mutation that
prevents a fatal outcome interferes with one of these
specific virus–cell interactions and interrupts the patho-
genetic sequence at the point where that interaction is
required for progression of the disease. With respect to
that particular mutation, the interaction point becomes
an in vivo genetic screen for reversion, so that virus
opulations isolated downstream of the inhibited inter-
ction will be highly enriched in revertants capable of
vercoming or circumventing the block imposed by the
riginal mutation. Therefore, the examination of multiple
ndividual mutants, each of which fails to cause death of
he animal, in conjunction with an analysis of their rever-
ants, will identify those interactions necessary for dis-
ase progression. This information is of critical impor-
ance in the development of intelligent vaccine and/or
herapeutic strategies, and it is this genetic approach to
EE pathogenesis that we have taken in the present
xperiments.
VEE causes equine enzootic and epizootic disease in
ropical areas of the Western hemisphere. Human cases
f VEE infection are associated with epizootics and may
resent as a mild flu-like febrile illness with pharyngitis,
fulminate febrile illness, or in approximately 1% of
ases, encephalitis. Severe disease tends to occur pref-
rentially in children (Ehrenkranz and Ventura, 1974).
ecent outbreaks of VEE serve as reminders of the
eterinary and medical threat of this disease (Rico-
esse et al., 1995; Rivas et al., 1997; R. Tesh and S.
Weaver, personal communication). In experimental infec-
tion of equines (burros), and in several other experimen-
tal models including the mouse, VEE progresses via
distinct lymphotropic and neurotropic phases (Gleiser et
al., 1962). The clinical features and autopsy findings in
human cases also suggest a biphasic pattern with se-
quential lymphoid and central nervous system involve-
ment (Johnson et al., 1968).
In this article, we describe the initial stages in VEE
pathogenesis comparing molecularly cloned viruses:
wild-type V3000, a single-site attenuated mutant, V3010,
and V3533, a second-site revertant of V3010 based on a
biological isolate from V3010-infected mice. The mutationin V3010 blocks progression of virus disease at an early
step in the VEE pathogenetic sequence, and the second-
site mutation in V3533 overcomes this early block.
RESULTS
Patterns of V3010 spread in the mouse
V3010 is a molecularly cloned mutant of VEE that is
isogenic with the wild-type clone, V3000, except for a Lys
for Glu substitution at codon 76 of the E2 glycoprotein
gene (Davis et al., 1991). While V3000 is uniformly fatal at
a standard dose of 1000 PFU administered subcutane-
ously (sc) in the footpad, V3010 is avirulent in outbred
CD-1 mice (Grieder et al., 1995). Following footpad inoc-
ulation, V3000 rapidly spreads to the draining popliteal
lymph node, where replication can be detected as an
increase in plaque numbers within 4 h postinfection (p.i.).
A viremia is well established by 12 h, virus is growing in
all other lymphoid tissues by 18 h, and within 24–36 h,
invasion of the central nervous system (CNS) is ob-
served (Grieder et al., 1995; Charles et al., 1995; Fig. 1,
row A). In contrast, the spread of V3010 to the draining
lymph node and beyond was altered. In approximately
25% of the animals inoculated with V3010, the spread of
the virus to the draining lymph node was delayed
(Grieder et al., 1995; Fig. 1, row B), while in the remainder
of animals, this delay was either reduced or undetect-
able (Fig. 1, row C). However, in all cases dissemination
of the virus beyond the draining lymph node to serum
and other tissues was sporadic. The basis for this range
of V3010 phenotypes has not yet been examined and
could be explained, for example, as a function of host
genotype differences in an outbred mouse population or
as a stochastic effect. Regardless, however, these re-
sults clearly suggest that the V3010 lesion at E2 76
confers both a significant impairment in spread of the
virus to the draining lymph node and a more substantial
block to spread beyond the draining lymph node.
V3010 reversion in vivo
Reversion analysis was utilized to determine more
accurately the step in the VEE pathogenetic sequence at
which the lesion in V3010 blocked progression of dis-
ease. If the block is at the level of the draining lymph
node, then it should function in vivo as a genetic screen
for the selection of revertants capable of proceeding
through that pathogenetic step. This suggests that a high
proportion of viruses isolated from sites downstream of
the putative blocked step should be same-site or sec-
ond-site revertants. The sporadic isolation of virus from
tissues downstream of the draining lymph node is con-
sistent with this hypothesis.
Table 1 shows the virulence and amino acid encoded
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113EARLY STEPS IN PATHOGENESIS OF VENEZUELAN EQUINE ENCEPHALITIS VIRUSat E2 76 of 17 isolates recovered from the draining lymph
node, spleen, and brain at 120, 96, and 72 h, respectively,
after inoculation with V3010. All the isolates from brain
appeared to be same-site revertants characterized by
the wild-type Glu residue at E2 76, 100% mortality, and an
average survival time not significantly different from that
characteristic of V3000. From spleen, the isolates had
reverted to wild-type Glu at E2 76, but 4 of the 5 isolates
displayed less than 100% mortality. This suggests a com-
plex genotype that includes the wild-type residue at E2
76, which may allow progression beyond the draining
lymph node, as well as one or more other mutations that
block disease progression at an undetermined point
downstream of the draining lymph node. Of similar com-
plexity, 6 of 6 isolates from the draining lymph node
FIG. 1. In vivo replication of V3000 and an avirulent mutant, V3010. Six
000 PFU of V3000 (Row A, virulent wild type) or V3010 (Rows B an
epresentative of the two different profiles of V3010 spread. At the indic
nd selected tissues were harvested for viral titer determinations. Li
etection indicate a titer at or below the limit.retained the mutant E2 Lys 76, but 3 of these showed
significant mortality compared to V3010, which is essen-tially avirulent. Overall, 11 of 11 isolates from spleen and
brain had an altered phenotype and/or genotype com-
pared with the inoculated V3010, and 3 of 6 isolates from
the draining lymph node had an altered phenotype sug-
gestive of a second-site reversion. This is consistent with
a genetically specified block to V3010 movement beyond
the draining lymph node.
In a second experiment, several plaque isolates
were recovered from serum, draining lymph node, and
contralateral popliteal lymph node from two individual
mice 24 h after sc inoculation with V3010 (Table 2).
Virus recovered from the draining lymph node formed
uniformly small plaques on BHK cells, resembling
those of parental V3010, whereas virus found in serum
and contralateral lymph node of these two mice dis-
eek-old CD-1 female mice were inoculated in the left rear footpad with
tenuated mutant: E2 Lys 76). Rows B and C show two experiments
tervals p.i., two mice per group (solid and open bars) were sacrificed
etection was approximately 2 3 103, and bars drawn at the limit ofto 8-w
d C, at
ated inplayed an intermediate plaque morphology more like
that of V3000.
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114 ARONSON ET AL.Dissemination of putative revertants
The in vivo phenotype of two of the putative revertants
was examined. Seven-week-old female CD-1 mice were
T
Virulence and Sequence Characteristics o
Recovered from draining lymph node Recovere
Isolatea Mortalityb AST 6 SEc
E2 76
Residued Isolatea Mortalityb
L41 16.6 9.0 6 1.4 Lys Sp1 0
L42 0 — Lys Sp4 100
L43 0 — Lys Sp6 66.7
L47 0 — Lys Sp7 0
L48 50 9.3 6 0.6 Lys Sp8 66.7
L49 50 9.0 6 1.0 Lys V3000 100
V3000 100 7.7 6 0.6 Glu V3010 0
V3010 0 — Lys
a Plaque isolates were recovered from three V3010-inoculated anim
espectively, in an experiment analogous to that shown in Fig. 1. The
b Six CD-1 mice per isolate were inoculated sc in the left rear footp
recorded.
c Average survival time 6 standard error.
d Each isolate was sequenced across the E2 76 codon, from nt 8750
was observed.
TABLE 2
Partial Sequence Analysis of Serum and Lymph Node Isolates
Virus Source Plaque size E2 76 E2 116
3000 Inoculum Large Glu Lys
3010 Inoculum Small Lys Lys
a1 dln Small Lys Lys
a2 dln Small Lys Lys
a3 dln Small Lys Lys
a4 dln Small Lys Lys
a5 dln Small Lys Lys
b2 cpln Intermediate Lys Glu
s1 Serum Intermediate Lys Glu
s2 Serum Intermediate Lys Glu
s3 Serum Intermediate Lys Glu
s4 Serum Intermediate Lys Glu
s5 Serum Intermediate Lys Glu
s1 Serum Intermediate Lys Glu
s2 Serum Intermediate Lys Glu
s3 Serum Intermediate Lys Glu
s4 Serum Intermediate Lys Glu
s5 Serum Intermediate Lys Glu
Note. Plaque isolates were derived from two individual CD-1 mice (4
nd 6) inoculated 24 h previously in the left rear footpad with 1000 PFU
f the molecularly cloned attenuated mutant V3010. RT-PCR products
orresponding to the complete E2 and E1 genes were sequenced.
redicted amino acid at E2 codon 76 or 116 is indicated in the last
olumn. No additional mutations were identified in the region se-
uenced for any of these isolates. V3000, virulent wild-type VEE clone;
ln, draining popliteal lymph node (left); cpln, contralateral popliteal
ymph node (right).inoculated with 1000 PFU of expanded plaque isolates
designated 4b2 or 4s2, isolated from the contralateral
lymph node and serum, respectively, of the same animal.
One of eight 4b2-inoculated mice died (12.5%), but all
eight showed signs of illness by day 6 (Table 3). These
signs ranged from hunching and ruffling to hind limb
paresis. Three mice displayed transient hind limb pare-
sis by day 7, recovered, and survived challenge with
V3000. Isolate 4s2 had a similar virulence phenotype in
mice: 25% mortality, 62.5% morbidity, with two of the
survivors having experienced transient hind limb pare-
sis. The nature of the illness in these mice indicated the
presence of a systemic response to viral infection and, at
least in some cases, neuroinvasion. However, the full
virulence of the wild-type clone was not restored in these
biologic isolates.
The experiment illustrated in Fig. 2 was performed to
confirm that dissemination beyond the draining lymph
node was an inherent and reproducible feature of 4b2
and 4s2 isolates. Naive mice were inoculated sc in the
left rear footpad with 4b2 or 4s2, and the spread of virus
was traced to selected tissues during the first 48 h p.i.
The pattern of viremia produced by 4b2 and 4s2 paral-
leled that of V3000. Like wild-type V3000, 4b2 and 4s2
produced maximal or close to maximal serum viral titers
by 12 h p.i., the time point illustrated in Fig. 2. In contrast,
at 12 h p.i. the serum titer in V3010-inoculated mice was
below the limit of detection (33 PFU/ml). At 24–48 h p.i.,
V3010 displayed viremia only sporadically (data not
shown). It is likely that this relatively late viremia re-
flected revertants in serum, although in this experiment
es Recovered from V3010-Infected Mice
spleen Recovered from brain
6 SEc
E2 76
Residued Isolatea Mortalityb AST 6 SEc
E2 76
Residued
— Glu B1 100 8.0 6 0.6 Glu
0 6 0.9 Glu B2 100 6.8 6 1.2 Glu
0 6 0 Glu B3 100 6.7 6 0.8 Glu
— Glu B6 100 7.3 6 0.8 Glu
5 6 0.7 Glu B7 100 6.8 6 0.8 Glu
7 6 1.2 Glu B8 100 6.8 6 0.8 Glu
— Lys V3000 100 6.7 6 1.2 Glu
V3010 0 — Lys
120, 96, and 72 h p.i. from the draining lymph node, spleen, or brain,
were expanded by one passage on BHK cells.
1000 PFU, and percentage mortality and average survival time were
(codons 63–112). Either no change or change only at the E2 76 codonABLE 1
f Virus
d from
AST
7.
10.
8.
6.
als at
isolates
ad withlarger plaque variants were not recovered from serum or
other sites. Peak serum viral titers produced after inoc-
FU of th
f resis.
115EARLY STEPS IN PATHOGENESIS OF VENEZUELAN EQUINE ENCEPHALITIS VIRUSulation with 4b2 or 4s2 were about one order of magni-
tude lower than those for V3000. Thus, although rever-
tants 4b2 and 4s2 were capable of overcoming the E2
T
Morbidity and Mort
Virus Codon at E2 76/116
Percentage m
(sick/to
Exp
V3010 Lys/Lys 0 (0/
4b2 Lys/Glu 100 (8/
4s2 Lys/Glu 62.5 (5/
Exp
V3000 Glu/Lys 100 (4/
V3010 Lys/Lys 0 (0/
V3533 Lys/Glu 87.5 (7/
V3048 Glu/Glu 100 (8/
a Six to 8-week-old female CD-1 mice were inoculated sc with 1000 P
or signs of illness ranging from hunching and ruffling to hind limb pa
FIG. 2. Early dissemination of V3010 and its revertants. Six to 8-week-
old CD-1 female mice were inoculated in the left rear footpad with 1000
PFU of V3000 (wild-type, filled circles), V3010 (cloned mutant, open circles),
4b2 (biological revertant, open squares), or 4s2 (biological revertant, open
inverted triangles). At intervals through 48 h, three mice were sacrificed
and tissues removed for titration. Shown are the serum samples from
animals sacrificed at 12 h, the time at which V3000 had an established
viremia. All three V3010-inoculated animals were below the limit of detec-
tion (33 PFU/ml), but are plotted at 30, 33, and 36 PFU for clarity. The
samples depicted from the right (contralateral) popliteal lymph node are
from animals sacrificed at 24 h, the time at which V3000 titers were at or
near their peak in this tissue (limit of detection is 333 PFU/g).Lys 76 specified block to spread beyond the draining
lymph node, they were still impaired in terms of their
quantitative ability to produce V3000 levels of viremia
and virulence.
The popliteal lymph node from the leg opposite the
inoculated footpad, the contralateral lymph node, is a
remote lymphoid site not directly linked via lymphatics
with the draining lymph node of the inoculated leg. V3000
and revertants 4b2 and 4s2 spread to this site with nearly
indistinguishable kinetics (Fig. 2 shows the titer in the
contralateral popliteal lymph node at 24 h p.i.). As ex-
pected, the isolate derived from contralateral lymph node
(4b2), as well as the serum isolated from the same
mouse (4s2), reached and replicated in this site as effi-
ciently as did V3000. However, of the three mice inocu-
lated with V3010 and sampled at 24 h p.i., virus titer in the
contralateral popliteal lymph node was at or near the
limit of detection (333 PFU/g). These observations indi-
cated that 4b2 and 4s2 resembled V3000 rather than
parental V3010 in terms of their ability to produce viremia
and spread to distant lymphoid sites. Hence, they were
revertants with respect to the restricted early spread
phenotype of V3010.
Identification of putative reverting mutations
Partial sequence analysis of the E2 glycoprotein gene
of putative revertants (including 4b2 and 4s2) identified a
second-site mutation that correlated with spread beyond
the inoculated leg and its draining lymphatics. All 11
isolates from serum and the contralateral popliteal lymph
node retained the attenuating residue at E2 76, but they
also possessed a mutation at nucleotide 8909, which
changed the amino acid at E2 116 from Lys to Glu (Table
2). The identical mutation at E2 116 was found in isolates
V3010 Revertants
ya Percentage mortality
(dead/total) AST 6 SE (days)
t 1
0 (0/8) —
12.5 (1/8) 8.0
25 (2/8) 8.0 6 1.4
t 2
100 (4/4) 7.0 6 1.2
0 (0/4) —
25 (2/8) 9.5 6 0.7
100 (8/8) 6.4 6 0.9
e indicated virus into the left rear footpad. The animals were observedABLE 3
ality of
orbidit
tal)
erimen
8)
8)
8)
erimen
4)
4)
8)
8)from two separate mice. By contrast, 5 of 5 small plaque
isolates from the draining (ipsilateral) lymph node were
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116 ARONSON ET AL.genotypically identical (within the region sequenced) to
the inoculated V3010 at E2 76 and E2 116. Thus, the
second-site mutation at E2 116 was found only in plaque
isolates recovered from sites distal to the draining lymph
node in the pathogenetic sequence. This reinforces the
suggestion that the E2 76 mutation in V3010 prevented
systemic spread of V3010 and that an additional muta-
tion(s) was required to enable V3010 to spread to serum
and distant lymphoid sites.
Phenotypic analysis of a molecularly cloned E2 76/E2
116 revertant (V3533)
To confirm that the revertant phenotype demonstrated
for 4b2 and 4s2 (i.e., viremia and early dissemination
competence) was attributable to the E2 116 mutation, this
mutation was placed into the genetic background of
V3010, resulting in a double mutant (V3533: E2, E76K, and
K116E). The E2 116 mutation also was placed into the
V3000 background as a single mutant (V3048). Table 3
displays mortality data for mice inoculated with V3000,
V3010, V3533, and V3048. The E2 116 mutation by itself
(V3048) did not affect virulence relative to V3000. The
cloned revertant (V3533) had virulence characteristics
intermediate between those of V3000 and V3010, resem-
bling the biologic revertants 4b2 and 4s2.
The pattern of early spread for V3533 showed striking
fidelity to that for the biological revertants 4b2 and 4s2
(Figs. 2 and 3; additional data not shown). The pattern of
peripheral replication of V3533 was similar, although not
identical, to that of V3000. Relative to V3000, there were
no discernable delays in reaching the draining lymph
node or in development of viremia. However, the viremia
generated by V3533 was of slightly lower titer and of
shorter duration than that for V3000. Likewise, the first
appearance and peak titers of V3533 in other lymphoid
tissues (spleen, contralateral lymph node, and thymus)
were similar to those characteristic of V3000. However,
the highest titers were not sustained as long, and clear-
ance from these tissues appeared to be somewhat more
rapid than in V3000-inoculated animals. A similar pattern
was apparent in the pancreas, where no replication of
V3010 was detected; V3533 replication in the pancreas
was to lower titers and was cleared more rapidly than
V3000 (data not shown). Replication in muscle was rarely
detected with any of these viruses and then only at titers
just above the limit of detection. Although V3533 first
appeared in the brain about the same time as V3000,
CNS titers of V3533 were more variable, the peak titers
were lower, and most importantly, the virus was cleared
from the brain. A large proportion of V3533-infected an-
imals survived. Therefore, the reversion conferred by the
second-site suppressor mutation at E2 116 was with
respect to the specific block in the pathogenetic se-
quence imposed by the E2 76 mutation in V3010 and was
not sufficient to restore virulence to the level of V3000.
o
iThis is consistent with the anatomical sites from which
the original biological revertants were isolated (serum
and contralateral lymph node; Table 2) and with the
presence of same-site revertants in the brain (Table 1).
V3048, carrying the E2 116 mutation alone, was indis-
tinguishable from V3000 in all tissues examined except
the pancreas, where it replicated to lower titers (data not
shown).
Replication at the site of inoculation
Many viruses are thought to replicate first at the site of
inoculation followed by movement through the lymphat-
ics to the draining lymph node, in concert with general
models of virus infection (Fenner, 1949; Nathanson, 1980;
Mims et al., 1995). VEE, however, does not appear to
follow this paradigm. As noted previously, V3000 titers at
the footpad site of inoculation did not exceed levels
consistent with recovery of the virus inoculum until 12 to
18 h p.i. (Grieder et al., 1995; data not shown), whereas
eplication in the draining lymph node was evident within
h (Fig. 3). These data suggest that spread of VEE to the
ymph node from the footpad is independent of replica-
ion at the site of inoculation. Replication evident in the
ootpad at 24 h or more p.i. could result from retrograde
pread of the virus from the draining lymph node back
own the inoculated limb or from the viremia. Viral titers
n the footpad over the course of V3010 infection indicate
hat the mutant also is deficient in movement of virus
ack to the footpad and/or the ability to replicate in this
issue (data not shown). V3533, 4b2, and 4s2 were indis-
inguishable from V3000 in this phenotype.
Histopathological examination of footpads from
3000-inoculated mice 24 h p.i. showed focal coagula-
ive necrosis involving skeletal muscle interstitium, rare
yofibers, and areolar connective tissues of the foot. A
parse focal infiltrate of neutrophils accompanied this
ecrosis. V3010-inoculated footpads, observed at the
ame time p.i., showed scanty necrosis and inflamma-
ion, qualitatively similar to, but of considerably lesser
egree than that seen in V3000-infected mice (data not
hown).
Patterns of virus-specific in situ hybridization signal at
4 h p.i. corresponded with footpad viral titers (Fig. 4).
ense signal was seen in the footpads for V3000- and
s2-infected mice (Figs. 4A and 4C), while very sparse
ignal was evident in some sections of V3010-inoculated
ootpads (Fig. 4B) after identical exposures and under
dentical hybridization conditions. V3000 replicated in the
oft tissue and collagenous connective tissue of the
ootpad, particularly in the dermis, skeletal muscle, and
endon, with a striking predilection for periosteum and
ndosteum (Fig. 4D). V3000 tended to spread and repli-
ate in a lamellar fashion, with signal focused in sheets
f contiguous fibroblasts. Signal was seen in this pattern
n the proximal leg, particularly involving the periosteum.
Vperime
117EARLY STEPS IN PATHOGENESIS OF VENEZUELAN EQUINE ENCEPHALITIS VIRUSIn addition, a concentration of silver grains was ob-
served over spindled cells of the skeletal muscle inter-
stitium, tendon, periosteum, and dermis (Fig. 4F). In con-
trast, V3010 replication was undetectable (even after
extended exposures) or was observed rarely as a
sparse, spotty signal (Fig. 4B). Replication in the spindled
cells of the skeletal muscle was not observed in V3010-
infected animals. The revertant 4s2 showed a pattern
similar to that of V3000 (Figs. 4C and 4E). These results
indicate a differential ability of V3000 and V3010 to rep-
licate in fibroblasts and the unidentified spindled cells in
the skeletal muscle interstitium, while the E2 116 sec-
FIG. 3. In vivo replication of cloned VEE strains with mutations at E2
the left rear footpad with 1000 PFU of V3000 (wild-type; E2 Glu 76, Lys
76, Glu 116). At the indicated intervals p.i., two mice per group (solid a
lymph node, contralateral (right) popliteal lymph node, spleen, thymus, p
of detection was approximately 2 3 103, and bars drawn at the limit o
more limited subset of tissues using cloned viruses, and analogous ex
results.ond-site suppressor mutation appeared to restore this
capacity. Alternatively, if viremia is required to seed these
s
Vsites, then lack of signal may be secondary to the re-
duced viremia in V3010-infected animals.
DISCUSSION
Earliest stages of VEE infection and movement to the
draining lymph node
The classical description of viral pathogenesis holds
that viruses first replicate at the site of inoculation fol-
lowed by spread to the draining lymph node (Fenner,
1949; Nathanson, 1980; Mims et al., 1995). In the case of
EE, however, several lines of evidence suggest that the
es 76 and 116. Six to 8-week-old CD-1 female mice were inoculated in
010 (E2 Lys 76, Lys 116), V3533 (E2 Lys 76, Glu 116), or V3048 (E2 Glu
n bars) were sacrificed and serum, footpad, ipsilateral (left) popliteal
s, muscle, and brain were harvested for viral titer determinations. Limit
tion indicate a titer at or below the limit. A second experiment with a
nts with V3010 and the biological revertants 4s2 and 4b2, gave similarresidu
116), V3
nd ope
ancrea
f detecite of initial replication is the draining lymph node itself.
EE replication in the draining lymph node was demon-
e118 ARONSON ET AL.strated within 4–6 h p.i., earlier than at any other ana-
tomical site including the footpad where the virus was
FIG. 4. In situ hybridization of inoculated legs. CD-1 mice were
inoculated sc in the left rear footpad with 1000 PFU, sacrificed, and
analyzed by in situ hybridization. (A) A histologic section of footpad
from a V3000-inoculated mouse at 24 h p.i. shows specific signal in the
subcutaneous muscle (original magnification 1003). (B) A comparable
section from a V3010-inoculated mouse subjected to in situ hybridiza-
tion lacked silver grains (original magnification 1003). (C) Footpad from
a 4s2-inoculated mouse shows a pattern of virus localization similar to
that for V3000 (original magnification 1003). (D) Silver grains were
concentrated in the area of the periosteum of the foot in a V3000-
inoculated mouse (arrows). b, bone; m, muscle (original magnification
2003). (E) A similar periosteal distribution of virus (arrows) was ob-
served in a 4s2-inoculated mouse. b, bone; m, muscle (original mag-
nification 2003). (F) In mice infected with V3000 or revertants, specific
signal was distributed over spindled cells of the skeletal muscle inter-
stitium (arrows) rather than over the muscle cells themselves (*).
(V3000-infected mouse, 24 h p.i., original magnification 2003). Compa-
rable results were obtained in separate experiments with V3000 and
V3010.inoculated sc (Grieder et al., 1995). A second line of
vidence (MacDonald and Johnston, 2000) derives fromstudies that utilized VEE replicon vector particles (VRP;
Pushko et al., 1997) expressing the green fluorescent
protein gene (gfp; Cormack et al., 1996) in place of the
VEE structural protein genes. The gfp–VRP unequivocally
mark the first cell infected in vivo (because the replicon
RNA lacks the structural protein genes), and the cell
specificity of the VRP infection is dependent on the gly-
coproteins with which the VRP are assembled. The re-
sults of the VRP experiments are most consistent with
infection of Langerhans cells in the footpad followed by
migration of these cells to the draining lymph node
where, in a V3000 infection, the earliest virus replication
would be detected.
The E2 76 mutation in V3010 affects this process. In
about 25% of animals infected with V3010, there was a
delay in detection of replication in the draining lymph
node, although the extent of eventual replication in these
instances appeared close to wild-type levels. This indi-
cates that movement of V3010 to the node was impaired
to some extent. However, in the majority of animals, this
impairment was much less apparent or undetectable,
suggesting that V3010 spread to the lymph node oc-
curred on a stochastic basis by a means different from
that employed by V3000 and that this process was some-
what less efficient. Using gfp–VRP packaged in V3010
glycoproteins (MacDonald and Johnston, 2000), a small
number of infected cells (relative to V3000 packaged
gfp–VRP) were observed in the draining lymph node at
12 h p.i. These were unidentified small round cells in the
medulla of the node, which also were observed as a
minority population of infected cells with the V3000 pack-
aged gfp–VRP. As V3010 fails to infect Langerhans/den-
dritic cells, its spread from the footpad could not take
advantage of the rapid and efficient movement of these
cells to the draining lymph node. Therefore, with limited
replication of V3010 in fibroblasts (see Fig. 4), the mutant
may rely on simple lymph drainage to move the inoculum
virus to the node, a process that is unlikely to be as
efficient as that employed by V3000. In the case of the
pattern displayed in Fig. 1b, limited replication of V3010
at the inoculation site may be the source of revertants
detected eventually in lymphoid tissues.
A second possibility is that the mutation in V3010
effectively blocks movement to the draining lymph node
and that limited replication in the footpad allows the
selection of revertants capable of movement. If this were
true, then virus isolated from the node should always be
revertant. This was not the case. Two sets of isolates
from the draining lymph node were examined. In one set,
all the isolates (five of five) retained the original E2 Lys 76
mutation and the characteristic small plaque phenotype
of V3010. In the other set, six of six isolates retained E2
Lys 76, and three of these retained the avirulent pheno-
type of V3010. The other three isolates demonstrated
sufficient mortality to distinguish them from the inocu-
lated mutant. With the caveat that these isolates have not
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we conclude that reversion is not necessarily required
for V3010 to reach the draining lymph node but that the
altered cell tropism of this mutant results in less efficient
movement to the node.
This notion is supported by studies of V3533, which
consistently moves to the draining lymph node as effi-
ciently as wild-type. gfp–VRP packaged in V3533 glyco-
proteins regain the ability to infect dendritic cells, al-
though these do not appear to be precisely the same
subset of dendritic cells targeted by V3000 (MacDonald
and Johnston, 2000). These results suggest that the effi-
cient movement of V3000 to the draining lymph node is
genetically linked to its ability to infect dendritic cells but
that dendritic cell infection is not absolutely required for
the virus to eventually reach the draining lymph node.
Establishment of viremia
In contrast to movement of V3010 to the draining lymph
node, spread beyond this tissue does require a reversion
event. All virus isolates from serum (10/10), contralateral
popliteal lymph node (1/1), spleen (5/5), and brain (6/6)
from four different mice were genotypic and/or pheno-
typic revertants of the inoculated V3010. The molecularly
cloned revertant V3533 induced a viremia with the same
time course as V3000, although the peak titers were
reduced approximately one order of magnitude.
A feature common to all neurotropic arboviruses is the
ability to produce a prolonged high-titered viremia in
susceptible hosts. This event appears to be required
both for viral invasion of the CNS and for transmission to
other mammalian hosts by insect vectors (Janssen et al.,
1984). In several alphavirus (Grimley and Friedman, 1970;
Liu et al., 1970; Murphy et al., 1973) and bunyavirus
(Janssen et al., 1984; Griot et al., 1993) infections, virus
eplicates in skeletal muscle both at the site of inocula-
ion and at locations remote from it. Viral replication in
uscle is thought to fuel the viremia. VEE infection of
mmunocompetent adult mice lacks this striking skeletal
uscle tropism (Grieder et al., 1995; Charles et al., manu-
cript submitted for publication). Instead, VEE dissemi-
ates early to lymphoid tissue and replicates to high titer
here. While it is presumed that this lymphotropic phase
ustains the viremia, the mutant data indicate that the
uestion is more complex. V3010 (as well as another
utant, V3014; Grieder et al., 1995) can replicate in the
raining lymph node without the induction of a viremia,
uggesting that replication alone at this site is insuffi-
ient to fuel the viremia. The mutants may be incapable
f escaping from the lymph system, they may be unsta-
le in lymph or serum, or they may be cleared much
ore rapidly from the serum. Alternatively, replication atn as yet unidentified site may be the source of viremia
n VEE infection.
p
upread to other peripheral tissues and brain
The second-site suppressor mutation in V3533 over-
ame the failure of V3010 to establish a viremia but did
ot restore wild-type virulence. Replication of V3533 in
eripheral lymphoid tissues reached the approximate
evels characteristic of V3000, but these peak levels
ere not sustained for the same length of time prior to
learance. A more dramatic difference was observed in
he brain where the variation of virus titers between
nimals was more pronounced, the peak titers were not
s high, and clearance of virus resulted in the survival of
high proportion of V3533-infected animals. The V3533
uppressor mutation was selected in response to a ge-
etic screen at the level of viremia induction; therefore,
here was no selection for a wild-type phenotype. Rather,
he selective pressure was local and specific to the block
n the pathogenetic sequence imposed by the original
utation. In support of this notion was the finding that
rain isolates from V3010-infected animals appeared to
e same-site revertants that restored wild-type virulence.
tructure/function correlates within the E2 gene
Regions of the E2 glycoprotein near codon 116 have
een examined in several contexts. E2-120 was found to
e an important attenuating locus in the TRD-derived
accine strain TC-83 (Kinney et al., 1993). An attenuated
ariant of Ross River virus possessed five E2 mutations
ompared to wild-type; these included mutations at E2-3,
2-67, and E2-119 among others (Vrati et al., 1988). In
indbis virus, a mutation in the E2-114 codon is associ-
ted with attenuation of virulence in mice, rapid penetra-
ion in BHK cells, and altered reactivity with E2c mono-
lonal antibodies (Davis et al., 1986). This amino acid
esidue aligns very closely with E2 116 in VEE (Kinney et
l., 1986). Amino acid changes at positions 62, 96, or 159
n the E2 gene of Sindbis are associated with escape
rom neutralization by E2c monoclonal antibodies; some
utations in these sites were also able to suppress the
ttenuation imposed by the E2-114 mutation (Pence et al.,
990; Schoepp and Johnston, 1993). These disparate loci
n the Sindbis E2 glycoprotein may form a “pathogenesis
omain,” a folded structure composed of noncontiguous
mino acid residues that determine virulence properties
f the virus. In VEE, E2 76 and E2 116 may participate in
n analogous pathogenesis domain. Until detailed three-
imensional structural characterization of the virion sur-
ace is completed, however, these models remain highly
peculative.
mplications for live virus vaccines
The in vivo fate of the VEE attenuated mutants and
heir in vivo reversion can serve as a model for the
erformance of live virus vaccines in inoculated individ-
als and provides some rather straightforward sugges-
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120 ARONSON ET AL.tions regarding vaccine design. First, an attenuating mu-
tation early in the pathogenetic sequence would be pre-
ferred from a safety perspective. Slowing the
progression of disease near the beginning of the se-
quence will allow an effective innate response to control
the infection as the adaptive immune system is stimu-
lated. Selective pressure for reversion at an early
blocked step is not a selection for reversion to wild-type,
whereas a mutation that blocks a late event is likely to be
subject to pressure for reversion to full wild-type viru-
lence in order for the virus to complete the pathogenetic
sequence. A potential drawback in selecting a mutation
blocking an early pathogenetic event is the possibility of
suppressing replication at such an early stage that a
protective immune response is not induced. Thus, it is
theoretically possible to “overattenuate” a vaccine with a
single mutation. A second vaccine implication is that
multiple mutations are better than single mutations if
each of the multiple mutations blocks at a different step
in the sequence. If reversion pressure is specific to the
block, then double mutants are likely to require at least
two reversion events to revert to full virulence. However,
a single reversion event could conceivably circumvent a
double mutant in which each of the constituent muta-
tions blocked the same step. Third, in contrast to the
notion that a live virus vaccine should be largely disabled
in its general replicative capacity, a successful vaccine
will replicate very strongly in vivo but in a way that does
not cause overt disease. Given careful characterization
of candidate attenuating mutations, safe and effective
vaccines can be designed with a minimal number of
mutations. Such vaccines will be characterized by near
wild-type growth through some relatively early step in the
pathogenetic sequence but virtually no progression be-
yond that stage. This will lead to induction of a strong
immune response without risk of disease.
The pathogenetic sequence at the molecular level
It is clear that progression through the VEE pathoge-
netic sequence requires multiple but different interac-
tions between virus and specific cells in vivo. The muta-
ions we have used to date in defining these different
nteractions are in the glycoprotein genes, suggesting
hat at least some of these steps are governed by the
bility of the virus to attach to and infect different cell
ypes or by the ability of the glycoproteins to envelop
ufficient quantities of infectious virus in these cells. The
ubtlety of these differences is underscored by the fact
hat these are single-site mutants, predominantly in the
2 gene. In the context of receptor interactions, for ex-
mple, this means that a single amino acid substitution
hat substantially blocks interaction with the receptor on
ne differentiated cell type may have little or no effect onhe analogous interaction in a different cell. This sug-
ests a wide variety of viral glycoprotein–cell receptorinteractions, each of which differs from the others in
perhaps small but significant ways. Examination of these
interactions using the approach suggested here will al-
low the genetic linkage of subtle changes in virus–cell
interactions to specific alterations in the VEE pathoge-
netic sequence leading to fatal disease.
MATERIALS AND METHODS
Viruses and clones
Virus phenotypically indistinguishable from the Trin-
idad donkey strain of VEE (TRD-E1) was derived from the
full-length cDNA clone pV3000 as previously described
(Davis et al., 1989; Grieder et al., 1995). The clone pV3010
was derived by site-directed mutagenesis of pV3000 and
contains a single point mutation resulting in a Lys for Glu
substitution at E2 codon 76 (Davis et al., 1991). Infectious
transcripts were prepared by in vitro transcription of
linearized plasmid with T7 RNA polymerase. Transcripts
were transfected into baby hamster kidney (BHK) cells
using cationic liposomes (Lipofectin, BRL) according to
the manufacturer’s instructions or by electroporation. In-
fectious progeny virus was harvested from transfected
culture supernatants as soon as a significant cytopathic
effect was observed (approximately 36 h posttransfec-
tion). Infectious virus derived from pV3000 or pV3010 is
termed V3000 or V3010, respectively. All viral stocks were
stored in aliquots at 270°C and were tested in mice to
verify virulence phenotypes (percentage mortality and
average survival time) after intracranial and sc inocula-
tion. Virus stocks used in these experiments were the
transfected culture supernatants without further cell cul-
ture passage.
The E2 116 mutation (A to G at nt 8909) was introduced
into the structural genes of pV3000 (cloned in M13) using
the site-directed mutagenesis procedure of Kunkel (1985;
Davis et al., 1991). An 800-bp BstXI restriction fragment
comprising the mutagenized region was removed from
M13 RF and cloned into a pUC118-based shuttle vector
containing either pV3000 or pV3010 structural genes
from which the analogous BstXI fragment had been ex-
cised (Grieder et al., 1995). The E2 glycoprotein gene
was excised from each shuttle vector as an SpeI–SacI
restriction fragment containing the E2 116 mutation alone
or both E2 116 and E2 76 mutations. This fragment was
then substituted for the analogous fragment in the full-
length pV3000 clone. The entire SpeI–SacI replacement
was sequenced to confirm that the desired mutations
were the only ones present. The full-length clone con-
taining the E2 116 mutation alone was designated
pV3048; the clone containing mutations at codons 76 and
116 of E2 was designated pV3533. Virus stocks were
generated from these clones as described above.
In experiments of this type, it is possible to introduce
lethal mutations into the clone and still retrieve infectious
virus due to reversion after transfection of the RNA tran-
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121EARLY STEPS IN PATHOGENESIS OF VENEZUELAN EQUINE ENCEPHALITIS VIRUSscripts into cells. To ensure that this was not the case
with the mutations used here, specific infectivities of the
transcripts were determined by transfection of radioac-
tively labeled transcripts into BHK cells followed by aga-
rose overlay and development of plaques (Rice et al.,
987). All of the mutant transcripts had specific infectiv-
ties similar to transcripts derived from pV3000, indicat-
ng that the introduced mutations were not lethal with
espect to replication in BHK cells.
ells
BHK cells were maintained in Eagle’s minimum essen-
ial medium (MEM) supplemented with 10% donor calf
erum, 10% tryptose phosphate broth, 0.29 mg/ml L-glu-
amine, 100 U/ml penicillin, and 0.5 mg/ml streptomycin.
irus was quantitated by plaque assay on subconfluent
onolayers of BHK cells.
ice
Adult female CD-1 mice (6–8 weeks old), specific
athogen- and orphan parvovirus-free (Charles River),
ere maintained on standard lab chow and water ad
ibitum. Animals were acclimatized for 1 week in the
SL-3 facility before experimental manipulation. In all
xperiments, mice were inoculated sc in the left rear
ootpad with 1000 PFU of virus in 10 ml of phosphate-
buffered saline (PBS) (low endotoxin) with 1% DCS (PBS/
DCS) or 10 ml of diluent alone. All inocula were retitered
at the time of the experiment to ensure that mice had
received the appropriate dose.
Isolation of revertants
Candidate revertants were recovered as plaque iso-
lates from tissues of mice inoculated sc in the left rear
footpad with 1000 PFU of V3010. Isolates from brain
(B1–3; B6–8) were derived at 72 h p.i. from an animal that
had detectable virus in both the left (draining) and the
right popliteal lymph nodes, spleen, serum, thymus, pan-
creas, and brain. Isolates from the left popliteal lymph
node (L41–L43; L47–L49) were derived at 120 h p.i. from
a mouse with detectable virus in the left popliteal lymph
node and spleen. Isolates from the spleen (Sp1; Sp4;
Sp6–8) were derived at 96 h p.i. from a mouse with
detectable virus titers in the left popliteal lymph node,
spleen, thymus, and pancreas.
A second set of candidate revertants was isolated at
24 h p.i. from two individual mice inoculated as de-
scribed above with V3010. Serum and tissue homoge-
nates from spleen and right popliteal lymph node from
these two animals yielded predominantly larger plaques
than V3010 on BHK cells; V3010 produced small, angular
plaques. Virus from the left popliteal lymph node yielded
uniformly small plaques.RNA isolation and sequence analysis of biologic
isolates
Intracellular RNA was isolated from one 60-mm dish
corresponding to each expanded plaque isolate as fol-
lows. At 4 to 6 h p.i. dishes were rinsed with warmed
PBS. Total cellular RNA was isolated using the RNA-zol B
method (Cinna Biotecx, Houston, TX). The quantity and
quality of RNA were assessed initially by SDS–agarose
gel electrophoresis. E1 and E2 genes were amplified
separately by RT-PCR using primer pairs JFA-1 (virus
sense, 59-GACAGCCCTTTCAGTCGTCATGTG-39) and
c9918 (virus complement, 59-AAGGCGGCCAGAGGGAT-
AGC-39) for E2, and Vs1276 (virus sense, 59-ACCTGG-
AGTCCTTGGATCACC-39) and Vc11356 (virus comple-
ent, 59-TGCCAATCGCCGCGAGTTCTATGT-39) for E1.
everse transcription was carried out at 42°C for 30 min
n 20-ml reaction volumes containing 1 ml of total intra-
cellular RNA (approximately 200 ng), 1 pmol each for-
ward and reverse primer, 50 U MuLV-RT (Boehringer
Mannheim), 0.01 M DTT, 20 U RNAsin, 50 mM KCl, 10 mM
Tris–HCl, pH 8.3, 2.5 mM MgCl2, and 1 mM each dATP,
CTP, dGTP, and dTTP. Reverse transcriptase was heat-
nactivated by boiling of the samples for 2 min. Taq
olymerase (2.5 U, Boehringer Mannheim) was added in
uffer yielding final concentrations of 50 mM KCl, 10 mM
ris–HCl, pH 8.3, 2.0 mM MgCl2 in a final volume of 100
ml. PCR was performed in a Perkin–Elmer 4600 thermo-
cycler with the following cycling parameters: 93°C for 1
min; 42°C for 1 min; 72°C for 2 min; for 25 cycles. PCR
mixtures then were treated with DNase-free RNase to
inactivate infectious RNA, extracted with phenol/chloro-
form, and electrophoresed on 0.7% agarose gels. The
anticipated 1.6-kb E2 PCR product and 1.5-kb E1 PCR
product were visualized on ethidium bromide-stained
gels and purified from the gel using the GeneClean kit
(Bio101). Gel-purified PCR products were sequenced us-
ing the D Taq cycle sequencing kit (USB). 35S-labeled
products were separated on a denaturing, 6.5% acryl-
amide wedge gel and visualized by autoradiography af-
ter exposure of Kodak XAR5 film.
Assay for virulence
Six or eight CD1 mice for each group were inoculated
in the left rear footpad with 1000 PFU of the indicated
transfected culture supernatant (V3010, V3000, V3048,
V3533) or 1000 PFU of an expanded biologic isolate (4b2
or 4s2). Mice were observed daily, and the numbers of
dead and visibly ill mice (hunched, ruffled, depressed,
and/or paralyzed) were recorded. Results are reported
as the average survival time in days with standard error.
All mice surviving the 14-day observation period were
challenged with 104 PFU V3000 intraperitoneally to en-
sure that survival was due to attenuation of virulence
rather than failure of the initial inoculation.
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122 ARONSON ET AL.Examination of wild-type and mutant pathogenesis
To compare the ability of virus to disseminate beyond
the site of inoculation, groups of CD-1 mice were inoc-
ulated with 1000 PFU of virus in the left rear footpad as
described above. At intervals through 168 h p.i., two mice
from each group were anesthetized with metofane and
exsanguinated via the axillary artery into serum separa-
tor tubes. Additional samples for viral titration that were
collected from each animal included the following: foot-
pad (all soft tissue on the plantar aspect of the left foot,
removed to the bone with sterile scalpel blade), ipsilat-
eral (left) popliteal lymph node, contralateral (right) pop-
liteal lymph node, spleen, thymus, pancreas, muscle, and
brain. Tough tissues of the footpad were quickly minced
on ice with sterile scalpels, transferred to a tared sterile
microtube with pestle (Kontes), and triturated in 9 vol of
PBS/DCS. Soft tissue samples were placed directly into
tared microtubes with pestles, triturated in 9 vol of PBS/
DCS, and stored frozen at 270°C. Samples were thawed
and centrifuged at 15,000 g for 15 min to remove tissue
debris, and the clarified supernatants were plaque ti-
tered on BHK cells.
Histology and in situ hybridization
Two mice were inoculated in the left rear footpad with
V3000, V3010, 4s2, or diluent as described above and
sacrificed at 24 h p.i. The left popliteal lymph node was
dissected and fixed in neutral buffered formalin. The
remainder of the left leg was disarticulated at the hip,
soft tissues were sectioned to the bone, and the entire
leg was fixed in a decalcification solution of 4% parafor-
maldehyde, 8% EDTA in PBS, pH 6.6. Fixation/decalcifi-
cation was carried out at 4°C with one change of fixative
over 10 days. Tissues were subsequently processed
through graded alcohols, embedded in paraffin, and sec-
tioned at 3 mm onto Probe-on1 slides (Fisher Scientific).
Hematoxylin- and eosin-stained sections were examined
for lesions. Serial sections were used for in situ hybrid-
ization as described (Grieder et al., 1995). 35S-labeled
iboprobe was transcribed from a pGEM-3 plasmid con-
aining the subcloned PstI–SacI fragment from the struc-
ural gene region of pV3000. The resulting 678-nucleo-
ide riboprobe was complementary to viral message
ense RNA and hybridized with full-length or sub-
enomic viral mRNA across portions of the 6K and E1
enes. Control irrelevant probe was transcribed from a
GEM-4 transcription vector containing influenza hem-
gglutinin (HA) gene sequences (kindly provided by Dr.
ndrew Caton, Wistar Institute). In situ hybridization was
erformed exactly as described (Grieder et al., 1995).
ontrols for probe specificity included serial sections
ybridized with HA probe, and tissues from PBS-inocu-
ated control mice hybridized with VEE probe.ACKNOWLEDGMENTS
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